about
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control.Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in miceThe Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosisIncreased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis AntigenIdentification of a second Mycobacterium tuberculosis gene cluster encoding proteins of an ABC phosphate transporterMycobacterium tuberculosis with disruption in genes encoding the phosphate binding proteins PstS1 and PstS2 is deficient in phosphate uptake and demonstrates reduced in vivo virulenceThree different putative phosphate transport receptors are encoded by the Mycobacterium tuberculosis genome and are present at the surface of Mycobacterium bovis BCGA serine/threonine protein kinase from Mycobacterium tuberculosisProtein kinase G from pathogenic mycobacteria promotes survival within macrophagesGenetic resistance of mice to Mycobacterium paratuberculosis is influenced by Slc11a1 at the early but not at the late stage of infectionAnalysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected miceNovel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model.1,2,3,4,8,9,10,11-octahydrobenzo[j]phenanthridine-7,12-diones as new leads against Mycobacterium tuberculosis.2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis.Anti-mycobacterial activity of 1,3-diaryltriazenes.Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boostingPhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence.Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live Mycobacterium bovis BCGVaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infectionEvaluation of new vaccines in the mouse and guinea pig model of tuberculosisPathophysiology of antigen 85 in patients with active tuberculosis: antigen 85 circulates as complexes with fibronectin and immunoglobulin G.1,4-diarylpiperazines and analogs as anti-tubercular agents: synthesis and biological evaluation.T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections.Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.Buruli ulcer.Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infectionMapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis.T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy.Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccinesSurvival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin.Development of luminescent Mycobacterium avium subsp. paratuberculosis for rapid screening of vaccine candidates in miceMucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in miceSynthesis and antimycobacterial activity of analogues of the bioactive natural products sampangine and cleistopholine.On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.Pulmonary necrosis resulting from DNA vaccination against tuberculosis.M.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model.Pertussis serodiagnosis in Belgium from 1990 to 2009.Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults
P50
Q21144731-BE69D340-756B-4FAD-BB59-058355ED35C7Q24652935-4C162EAD-CB4B-4E09-908A-7DEFB374A2CBQ26852552-B1F981C3-13D2-4272-84FA-DFEF828DB8E0Q27302995-ECDED9BF-BC58-4576-A5A3-D7E566906FBFQ28292364-65196FF9-699B-4600-BB0C-7C2DC29D048AQ28486756-E35DC95C-3CF1-4BEE-8EB0-D43EEF29A705Q28487100-D6660B9B-C056-4157-9804-9726314694E2Q28487491-6EFFE929-CE0C-4805-AF85-06EB6A3F35CCQ28487580-47B53FF8-E0F2-45E7-BDC5-A243AE87E113Q28506280-EBF7E86D-9612-49F9-A80F-E9AE52735D32Q28538249-00CA8536-A3D2-470F-AAE5-01DCD26E77C1Q30352384-357D39BE-9837-4513-86D5-931B48040FCEQ30359991-4DD24A90-3168-405B-B825-7BBE117EDDB4Q30360780-EF8DF1EC-ACC3-4F7E-8D68-8F0C6C790674Q31154053-998DD07C-F9C2-4DE4-8694-D3C804FC28AFQ33324374-1334B87E-C88B-4D88-87CD-E0C280E55740Q33346189-C84B0088-33EE-4BBA-B30B-691870980E62Q33601206-6DAED98B-BB28-4E9D-A3BC-DC5639D62B1BQ33752344-080C3240-79AF-4664-B871-B0E423BE9FBEQ33755534-A8D0B1B8-2F1B-4A31-953E-7B372108B6A8Q34000178-000B9721-412A-472D-A4F7-CD44D163166CQ34149324-06D01259-3873-4F9E-82E7-618F4C09550EQ34169888-E064C181-FA98-4605-91B6-390438C342C2Q34193844-349EBA5D-25A7-41CA-B18E-96E8666B49A4Q34229628-A4A48FF1-1615-4312-B381-5418B3E62700Q34361636-1320C7C9-CDBE-443A-A20D-CFCD2EB7D73EQ34484151-CAEEE001-7074-4085-8EAF-29B76AEF9B24Q34525371-28F9CC34-252E-47C2-8780-B025CF7E2D4AQ34527217-12E7D857-DF42-4B98-A08D-3F578FAD7C1DQ34536007-F8A32F75-567D-44D5-BCDF-DD2FD30818EAQ34601896-F66FAF93-6725-4BF6-ADF8-905D8C6A0EBCQ34651109-D2DECDD7-7789-4819-BE6D-9F59D175B573Q34681116-5B57072C-0171-478F-B8D0-745E1D25343CQ34722855-68A5FC91-2F7C-4B41-AD57-0FF04215C005Q34816911-711858DF-B399-48AA-82B2-21FC43B4506CQ34852418-A0D49311-63AC-4802-80F7-561E85514C51Q34854656-CB868840-720E-4CF3-867A-573DFD453756Q35022769-5619A127-3FBD-4457-807A-4295A8FD6981Q35066316-4A91396D-FCA2-4C8E-9FC9-9566EDD8569DQ35140304-DD913701-928D-4D1D-BBF4-D430CAAC9BAD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kris Huygen
@ast
Kris Huygen
@en
Kris Huygen
@es
Kris Huygen
@nl
Kris Huygen
@sl
type
label
Kris Huygen
@ast
Kris Huygen
@en
Kris Huygen
@es
Kris Huygen
@nl
Kris Huygen
@sl
prefLabel
Kris Huygen
@ast
Kris Huygen
@en
Kris Huygen
@es
Kris Huygen
@nl
Kris Huygen
@sl
P106
P21
P31
P496
0000-0001-7808-0512